Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biomoda, a cancer diagnostics company, has received Mexican patent from Instituto Mexicano de la Propiedad Industrial (IMPI), for porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.
Subscribe to our email newsletter
Biomoda said that the Mexican patent #269352, ‘Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine,’ is exactly as its US patent 6,838,248, which was issued in 2005. Foreign equivalents are now effective in Mexico, Japan and Australia and are pending in Europe and Canada.
The 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine, or TCPP, is the foundation for several Biomoda product lines and medical diagnostics.
Additionally, Biomoda is organising Phase II clinical trials of its first product, an in-vitro test for the detection of early-stage lung cancer, in which study volunteers provide deep-lung sputum samples to be screened for cancer cells with the CyPath assay.